Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Marguerite Vignon, Valérie Lauwers‐Cancès et al.|Blood|2022Cited by 25
Treatment of Myeloma Cast Nephropathy (MCN): A Randomized Trial Comparing Intensive Haemodialysis (HD) with High Cut-Off (HCO) or Standard High-Flux Dialyzer in Patients Receiving a Bortezomib-Based Regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT))Frank Bridoux, Jean‐Paul Fermand, Arnaud Jaccard et al.|Blood|2016Cited by 15
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 studyArthur Bobin, Xavier Leleu, Salomon Manier et al.|Haematologica|2024Cited by 3
Time to Improve Bortezomib and Lenalidomide Lines of TherapyStéphanie Guidez, Hélène Demarquette, Denis Caillot et al.|University of Southern Denmark Research Portal (University of Southern Denmark)|2017Cited by 0
Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from ThalidomideHélène Demarquette, Xavier Leleu, Stéphanie Guidez et al.|Blood|2015Cited by 0